Anika TherapeuticsANIK -2.40%58 Quick Ratio is 3.37 as of Mar. 2026, which is 30% below its 10-year median of 4.82. GuruFocus rates ANIK with a GF Score™ of 58/100 and a GF Value™ of $20.54 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 995 Drug Manufacturers companies, Anika Therapeutics ranks better than 79.6% on this metric.
Anika Therapeutics has a quick ratio of 3.37. It generally indicates good short-term financial strength.
The historical rank and industry rank for Anika Therapeutics's Quick Ratio or its related term are showing as below:
ANIK'
s Quick Ratio Range Over the Past 10 Years
Min: 2.78 Med: 4.82 Max: 18.85
Current: 3.37
During the past 13 years, Anika Therapeutics's highest Quick Ratio was 18.85. The lowest was 2.78. And the median was 4.82.
ANIK's Quick Ratio is ranked better than 79.6% of 995
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs ANIK: 3.37
Anika Therapeutics (NAS:ANIK) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Anika Therapeutics Quick Ratio Related Terms
Anika Therapeutics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Anika Therapeutics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Anika Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anika Therapeutics Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Anika Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Anika Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Anika Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anika Therapeutics (ANIK) has a Quick Ratio of 3.37 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Anika Therapeutics and its competitors. This is 30% below median its historical median of 4.82. Over the past decade, Anika Therapeutics' Quick Ratio has ranged from 2.78 to 18.85. According to the industry distribution chart, Anika Therapeutics ranks #203 out of 995 companies in the Drug Manufacturers industry, placing it in the top 20.4%.
Is Anika Therapeutics' Quick Ratio too high?
Anika Therapeutics' current Quick Ratio of 3.37 is 30% below median its 10-year median of 4.82. Over the past 10 years, this metric has ranged from a low of 2.78 to a high of 18.85. The Drug Manufacturers industry median Quick Ratio is 1.45. Anika Therapeutics' value of 3.37 is 132.4% above this industry median. Based on the distribution chart, Anika Therapeutics ranks #203 out of 995 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Anika Therapeutics has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Anika Therapeutics' Quick Ratio compare to LFCR and DERM?
According to the Drug Manufacturers industry distribution chart, Anika Therapeutics ranks #203 out of 995 companies for Quick Ratio. This places Anika Therapeutics in the top 20% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.45. Anika Therapeutics' value of 3.37 is 132.4% above this benchmark. Historically, Anika Therapeutics' own Quick Ratio has ranged from 2.78 to 18.85 over the past decade. While the company's 10-year median is 4.82 vs. the industry median of 1.45, Anika Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 995 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anika Therapeutics's current Quick Ratio of 3.37 is 132.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Anika Therapeutics and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anika Therapeutics's current Quick Ratio is 3.37, which is 30% below median its own 10-year median of 4.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anika Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Anika Therapeutics (ANIK) is currently considered Modestly Undervalued. The stock's GF Value™ is $20.54, compared to a current price of $14.63 — trading 28.8% below its estimated fair value. The current Quick Ratio is 3.37, which is 30% below median its 10-year median of 4.82 and 132.4% above the Drug Manufacturers industry median of 1.45. Anika Therapeutics' overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Anika Therapeutics (ANIK), the current Quick Ratio is 3.37 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Anika Therapeutics (ANIK) Overvalued in 2026?
Based on GuruFocus' analysis, Anika Therapeutics stock appears to be undervalued.
The current stock price of $14.63 is trading 28.8% below its estimated GF Value™ of $20.54.
GuruFocus considers Anika Therapeutics to be Modestly Undervalued.
Key valuation signals for ANIK:
Quick Ratio: 3.37 (30% below median its 10-year median of 4.82)
GF Value™: $20.54 vs. price of $14.63 (28.8% below fair value)
Industry Position: 132.4% above the Drug Manufacturers median (#203 of 995)
No single metric tells the full story. See the ANIK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
58GF Score
Get the complete analysis for ANIK
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANIK has been successfully added to your 
